Hematopoietic Stem-Cell Transplantation versus Immunosuppressive Therapy in Patients with Adult Acquired Severe Aplastic Anemia: A Cost-Effectiveness Analysis

References

• Young NS, Longo DL. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656. doi:10.1056/NEJMra1413485
   PubMed Web of Science ®Google Scholar
• Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95(12):2119–2125. doi:10.3324/haematol.2010.026682
   PubMed Web of Science ®Google Scholar
• Passweg JR, Marsh JCW. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology. 2010;2010(1):36–42. doi:10.1182/asheducation-2010.1.36
   PubMed Web of Science ®Google Scholar
• Dufour C, Paul V, Elisa C, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4):585–594.
   PubMed Web of Science ®Google Scholar
• Contejean A, Resche-Rigon M, Tamburini J, et al. Aplastic anemia in the elderly: a nationwide survey on behalf of the French reference center for aplastic anemia. Haematologica. 2019;104(2):256–262. doi:10.3324/haematol.2018.198440
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: outcome of 955 patients treated 2001–2012. Am J Hematol. 2018;93(5):643–648. doi:10.1002/ajh.25081
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–438. doi:10.1056/NEJMoa1103975
   PubMed Web of Science ®Google Scholar
• Scheinberg P. Recent advances and long-term results of medical treatment of acquired aplastic anemia. Hematol Oncol Clin North Am. 2018;32(4):609–618. doi:10.1016/j.hoc.2018.03.003
   PubMed Web of Science ®Google Scholar
• Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018;124(21):4192–4201. doi:10.1002/cncr.31658
   PubMed Web of Science ®Google Scholar
• Deeg HJ. More than one angle to target aplastic anemia? Cancer. 2018;124(21):4165–4167. doi:10.1002/cncr.31656
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207. doi:10.1111/bjh.13853
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11–18. doi:10.3324/haematol.10075
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Sica S. Alternative donor transplants for severe aplastic anemia: current experience. Semin Hematol. 2016;53(2):115–119. doi:10.1053/j.seminhematol.2016.01.002
   PubMed Web of Science ®Google Scholar
• Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2(15):2020–2028. doi:10.1182/bloodadvances.2018021162
   PubMed Web of Science ®Google Scholar
• Li Y, Duan F, Xiao H, et al. Therapeutic outcomes of haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia: a multicenter study. Transplantation. 2018;102(10):1724–1731. doi:10.1097/TP.0000000000002200
   PubMed Web of Science ®Google Scholar
• George B, Nisham PN, Devasia AJ, et al. Post-transplant cyclophosphamide as sole graft-versus-host disease prophylaxis is feasible in patients undergoing peripheral blood stem cell transplantation for severe aplastic anemia using matched sibling donors. Biol Blood Marrow Transplant. 2018;24(3):494–500. doi:10.1016/j.bbmt.2017.10.034
   PubMed Web of Science ®Google Scholar
• Rice C, Eikema DJ, Marsh JCW, et al. Allogeneic hematopoietic cell transplantation in patients aged 50Years or older with severe aplastic anemia. Biol Blood Marrow Transplant. 2019;25(3):488–495. doi:10.1016/j.bbmt.2018.08.029
   PubMed Web of Science ®Google Scholar
• Giammarco S, Peffault de latour R, Sica S, et al. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018;131(17):1989–1992. doi:10.1182/blood-2017-09-807859
   PubMed Web of Science ®Google Scholar
• DeZern AE, Brodsky Robert A. Clinical management of aplastic anemia. Expert Rev Hematol. 2011;4(2):221–230. doi:10.1586/ehm.11.11
   PubMed Web of Science ®Google Scholar
• Kahn Q, Ellis RJ, Skikne BS, et al. A retrospective analysis of long-term survival in severe aplastic anemia patients treated with allogeneic bone marrow transplantation or immunosuppressive therapy with antithymocyte globulin and cyclosporin A at a single institution. Mil Med. 2002;167(7):541–545. doi:10.1093/milmed/167.7.541
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol. 2016;104(2):168–174. doi:10.1007/s12185-016-2037-8
   PubMed Web of Science ®Google Scholar
• Arranz R, Otero M-J, Ramos R, et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplant. 1994;13(4):383–387.
   PubMed Web of Science ®Google Scholar
• George B, Mathews V, Viswabandya A, et al. Immunosuppressive therapy and bone marrow transplantation for aplastic anaemia - the CMC experience. J Assoc Physicians India. 2015;63:36–40.
   PubMedGoogle Scholar
• Ahn MJ, Choi JH, Lee YY, et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol. 2003;78(2):133–138. doi:10.1007/BF02983381
   PubMed Web of Science ®Google Scholar
• Doney K, Leisenring W, Storb R, et al. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med. 1997;126(2):107–115. doi:10.7326/0003-4819-126-2-199701150-00003
   PubMed Web of Science ®Google Scholar
• Viollier R, Passweg J, Gregor M, et al. Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol. 2005;84(1):47–55. doi:10.1007/s00277-004-0930-3
   PubMed Web of Science ®Google Scholar
• Kim I, Yoon SS, Park S, et al. The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea. J Korean Med Sci. 2003;18(3):365–371. doi:10.3346/jkms.2003.18.3.365
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436. doi:10.1182/blood-2016-08-693481
   PubMed Web of Science ®Google Scholar
• de Planque MM, Richel DJ, Fibbe WE, et al. Acquired severe aplastic anaemia in adults--a single centre study with 13 years follow-up. Neth J Med. 1990;37(3–4):103–110.
   PubMed Web of Science ®Google Scholar
• Peinemann F, Grouven U, Kroeger N, et al. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS One. 2011;6(4):e18572. doi:10.1371/journal.pone.0018572
   PubMed Web of Science ®Google Scholar
• Marsh JCW. Making therapeutic decisions in adults with aplastic anemia. Hematology. 2006;2006(1):78–85. doi:10.1182/asheducation-2006.1.78
   Google Scholar
• Prica A, Chan K, Cheung M. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis. Neuro-Oncol. 2014;16(10):1384–1391. doi:10.1093/neuonc/nou057
   PubMed Web of Science ®Google Scholar